Project Grant R43DK117752

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $817,161 to Mercer University to investigate the use of gut-derived mesenchymal stem cells (MSCs) as a potential autologous cell therapy for the treatment of perianal fistulas, a serious complication associated with Crohn's disease. The key objectives are to characterize the potency and immunosuppressive properties...

This $790,359 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of a targeted probiotic yeast therapy for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The project aims to design, characterize, and optimize a nanobody drug-secreting Saccharomyces boulardii yeast therapeutic that can reduce inflammation and...

This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...

This National Science Foundation (NSF) Project Grant, awarded under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070), provides $168,690 to the Florida Institute of Technology Inc. (Florida TECH) to develop a theragnostic (therapeutic + diagnostic) system for inflammatory bowel diseases (IBD). The project aims to model the complex interplay of host, microbial, and environmental factors that trigger IBD using data science, and then leverage synthetic biology and...

This $2,842,245 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to elucidate the genetic regulation of intestinal epithelial cell injury in ulcerative colitis. The 4-year award to Mayo Clinic aims to: 1) delineate intestinal epithelial cell injury pathways that govern anti-TNF therapy effectiveness, and 2) discover predictive...

The National Cancer Institute awarded Endure Biotherapeutics, Inc. a $392,827 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel engineered native bacteria (ENB) therapy for the treatment of familial adenomatous polyposis (FAP), a hereditary condition that leads to colorectal cancer. The funding will support the company's research to engineer gut bacteria to express therapeutic gene products that can effectively colonize the gut and suppress the...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $458,047 Project Grant to Chapman University. The grant will fund a 3-year project to investigate how extracellular vesicles (EVs) produced by intestinal epithelial cells (enterocytes) mediate inflammation in inflammatory bowel disease (IBD). The project aims to identify the transcriptomic miRNA signature of EVs...

This $3,022,197 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to study the role of regulatory T (Treg) cells and the Treg-IL-27 axis in immune regulation, particularly in the context of inflammatory bowel disorders. The research aims to examine the molecular mechanisms driving elevated IL-27 expression in gut-associated Treg cells during inflammation, as well...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting research to investigate the role of the transcriptional repressor Aiolos in the pathogenesis of inflammatory bowel disease (IBD) in humans. The $234,000 award to the University of Colorado-Denver will fund studies to analyze how Aiolos regulates T cell activation and function, and...

This $2,736,640 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to characterize the diversity of innate lymphoid cell (ILC) subtypes and define their development, function, and spatial regulation. The research will investigate the developmental pathway of a specialized population of ROR𝛾t+T-bet+ ILCs and identify genetic mechanisms regulating...